0000000000570569

AUTHOR

G. Santoro

showing 4 related works from this author

SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study

2021

Abstract Background Preoperative SARS-CoV-2 vaccination could support safer elective surgery. Vaccine numbers are limited so this study aimed to inform their prioritization by modelling. Methods The primary outcome was the number needed to vaccinate (NNV) to prevent one COVID-19-related death in 1 year. NNVs were based on postoperative SARS-CoV-2 rates and mortality in an international cohort study (surgical patients), and community SARS-CoV-2 incidence and case fatality data (general population). NNV estimates were stratified by age (18–49, 50–69, 70 or more years) and type of surgery. Best- and worst-case scenarios were used to describe uncertainty. Results NNVs were more favourable in su…

MaleCOVID-19 Vaccinesafe surgery; vaccination modelling; COVID-19Vascular damage Radboud Institute for Health Sciences [Radboudumc 16]MULTICENTERComorbidity030230 surgery0302 clinical medicinephase 3 clinical trial (topic)Case fatality rateProspective StudiesSARS-CoV-2 Vaccination Safe surgeryCOVID-19/epidemiologySARS-CoV-2 ; vaccination ; safe surgeryeducation.field_of_studycase fatality rateVaccinationVaccinationAdolescent; Adult; Aged; COVID-19; COVID-19 Vaccines; Comorbidity; Elective Surgical Procedures; Female; Humans; Male; Middle Aged; Postoperative Complications; Preoperative Period; Prospective Studies; SARS-CoV-2; Vaccination; Young Adulthealth care policyElective Surgical Procedures030220 oncology & carcinogenesisvaccination modellingPreoperative PeriodCOVID-19; SARS-CoV-2; cancer; vaccination; outcome; mortality; infection; modellingCohort studyprospective studyHumanmedicine.medical_specialtyArticle03 medical and health sciencesSARS-CoV-2 vaccinationSDG 3 - Good Health and Well-beingCOVID-19 Vaccines/pharmacologyHumansVaccination/methodsElective surgeryeducationAgedScience & TechnologyElective Surgical Procedureadult; aged; Article; cancer grading; cancer surgery; case fatality rate; computer assisted tomography; elective surgery; female; follow up; health care policy; human; incidence; infection rate; infection risk; major clinical study; male; middle aged; mortality; outcome assessment; phase 3 clinical trial (topic); preoperative care; prospective study; sensitivity analysis; seroprevalence; Severe acute respiratory syndrome coronavirus 2; vaccination; young adult; COVID-19; COVID-19 Vaccines; Comorbidity; Elective Surgical Procedures; Postoperative Complications; Preoperative Period; SARS-CoV-2; Vaccination; surgery.Cura preoperatòriamajor clinical studymortalityinfectionProspective StudieincidenceSurgeryHuman medicinePostoperative Complication610 Medizin und GesundheitAcademicSubjects/MED00910Settore MED/18 - CHIRURGIA GENERALESettore MED/29 - CHIRURGIA MAXILLOFACCIALEcomputer assisted tomographyESTUDOS PROSPECTIVOSsurgerysafe surgeryPostoperative Complicationssensitivity analysisSevere acute respiratory syndrome coronavirus 2preoperative careVacunacióProspective cohort studyseroprevalenceIncidence (epidemiology)covidElective Surgical Procedures/methodsMiddle Agedcancer gradingCOVID vaccinationoutcome/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingSARS-CoV-2; vaccination; surgeryOriginal ArticleFemalecancer surgeryAcademicSubjects/MED00010Life Sciences & BiomedicineAdultCOVID-19 VaccinesAdolescentinternational prospective cohort studyPostoperative Complications/prevention & controlPopulationinfection rateSARS-CoV-2/immunologyNOmodellingYoung Adultmedicinefollow upcancerddc:610infection riskoutcome assessmentLS7_4business.industrySARS-CoV-2Number needed to vaccinatePreoperative careCOVID-193126 Surgery anesthesiology intensive care radiologySettore MED/18Reconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]elective surgeryEmergency medicinebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe British Journal of Surgery
researchProduct

Pruritus characteristics in a large Italian cohort of psoriatic patients

2019

Background: Psoriasis (Ps) is a chronic systemic autoimmune disease associated with pruritus in 64–98% of patients. However, few modestly sized studies assess factors associated with psoriatic pruritus. Objective: To investigate factors associated with Ps pruritus intensity. Methods: Psoriasis patients 18 years or older seen in one of 155 centres in Italy between September 2005 and 2009 were identified from the Italian PsoCare registry. Patients without cutaneous psoriasis and those with missed information on pruritus were excluded. Results: We identified 10 802 patients, with a mean age 48.8 ± 14.3 years. Mild itch was present in 33.2% of patients, moderate in 34.4%, severe in 18.7% and ve…

MaleCross-sectional studySeverity of Illness IndexCohort Studies030207 dermatology & venereal diseases0302 clinical medicineRisk Factorseducation; itch; pruritus; psoriasis; pustular psoriasis; treatment; Adolescent; Adult; Cohort Studies; Cross-Sectional Studies; Educational Status; Facial Dermatoses; Female; Foot Dermatoses; Genitalia; Hand Dermatoses; Humans; Italy; Male; Middle Aged; Pruritus; Psoriasis; Registries; Risk Factors; Severity of Illness Index; Sex Factors; Young AdultEpidemiologyitchRegistriesYoung adultskin and connective tissue diseaseseducationtreatmentMiddle AgedSettore MED/33 - MALATTIE APPARATO LOCOMOTOREInfectious Diseasespustular psoriasisItaly030220 oncology & carcinogenesisCohortEducational StatusPRURITIS EPIDEMIOLOGYFemaleSettore MED/35 - MALATTIE CUTANEE E VENEREECohort studyAdultmedicine.medical_specialtyAdolescentPSORIASDermatologyHand DermatosesArticle03 medical and health sciencesYoung AdultPharmacotherapySex FactorsSettore MED/35PsoriasisSeverity of illnessmedicineHumansPsoriasisGenitaliaFoot Dermatosesbusiness.industryPruritusmedicine.diseaseDermatologyPruritusItch sensationCross-Sectional StudiesbusinessFacial Dermatoses
researchProduct

Trend in rifampicin-, multidrug- and extensively drug-resistant tuberculosis in Italy, 2009-2016

2018

In Italy, rifampicin-resistant and MDR-TB were high in foreign-born persons, but decreased from 2009 to 2016

0301 basic medicinePulmonary and Respiratory MedicineExtensively Drug-Resistant TuberculosisAntitubercular AgentsEmigrants and ImmigrantsAntitubercular Agents; Emigrants and Immigrants; Extensively Drug-Resistant Tuberculosis; Humans; Italy; Mycobacterium tuberculosis; Rifampin; Tuberculosis Multidrug-ResistantMycobacterium tuberculosis03 medical and health sciences0302 clinical medicineTuberculosis Multidrug-Resistantpolycyclic compoundsmedicineTuberculosisHumansbiologybusiness.industryExtensively drug-resistant tuberculosisMycobacterium tuberculosisMultidrug-Resistantmedicine.diseasebiology.organism_classificationVirology030104 developmental biology030228 respiratory systemItalyRifampinbusinessRifampicinmedicine.drug
researchProduct

Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry

2014

Background: Some studies have shown that switching patients from one tumor necrosis factor (TNF)-alfa inhibitor to another may be beneficial when they have an inadequate response or an adverse event. Objective: We sought to assess the variables predicting the efficacy of the second TNF-alfa inhibitor in patients discontinuing the first TNF-alfa inhibitor. Methods: Data from all 5423 consecutive patients starting TNF-alfa inhibitor therapy for psoriasis between September 2005 and September 2010 who were included in the Italian Psocare registry were analyzed. Results: In 105 patients who switched to a second TNF-alfa inhibitor who had complete follow-up data, 75% improvement in the Psoriasis …

Maleprimary inefficacy75% improvement in the Psoriasis Area Severity Index score; PASI; PASI 75; Psoriasis Area Severity Index; TNF; biologics; efficacy; primary inefficacy; psoriasis; secondary loss of efficacy; switching; tumor necrosis factor; tumor necrosis factor-alfa inhibitors; Adult; Analysis of Variance; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Cohort Studies; Confidence Intervals; Dose-Response Relationship Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunoglobulin G; Italy; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Proportional Hazards Models; Psoriasis; Receptors Tumor Necrosis Factor; Registries; Retrospective Studies; Risk Assessment; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha; Young AdultSWITHCESefficacyTNFpsoriasis; psoriasis arthritis; pharmachological treatmentPASI 75Severity of Illness IndexReceptors Tumor Necrosis FactorEtanerceptCohort StudiesMonoclonalReceptorsSettore MED/35 - Malattie Cutanee E VenereeRegistriesHumanizedtumor necrosis factor-alfa inhibitors.switchingHazard ratioAntibodies MonoclonalMiddle AgedTreatment OutcomeItalyPredictive value of tests75% improvement in the Psoriasis Area Severity Index scoreFemaleDrugPsoriasis Area Severity IndexbiologicTNF-alphaAdultmedicine.medical_specialtytumor necrosis factorDermatology75% improvement in the Psoriasis Area Severity Index score; PASI; PASI 75; Psoriasis Area Severity Index; TNF; biologics; efficacy; primary inefficacy; psoriasis; secondary loss of efficacy; switching; tumor necrosis factor; tumor necrosis factor-alfa inhibitorsAntibodies Monoclonal Humanizedsecondary loss of efficacyRisk AssessmentAntibodiestumor necrosis factor-alfa inhibitorsDrug Administration ScheduleDose-Response RelationshipYoung AdultSettore MED/35Predictive Value of TestsInternal medicinePsoriasisSeverity of illnessmedicineConfidence IntervalsHumansPsoriasisbiologicsAdverse effectPsoriasis; TNF-alphaProportional Hazards ModelsRetrospective Studiespsoriasibiologics; efficacy; primary inefficacy; psoriasis; secondary loss of efficacy; switching; tumor necrosis factor-alfa inhibitors; Adalimumab; Adult; Analysis of Variance; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Cohort Studies; Confidence Intervals; Dose-Response Relationship Drug; Drug Administration Schedule; Etanercept; Female; Follow-Up Studies; Humans; Immunoglobulin G; Infliximab; Italy; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Proportional Hazards Models; Psoriasis; Receptors Tumor Necrosis Factor; Registries; Retrospective Studies; Risk Assessment; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult; 2708Analysis of Variancepharmachological treatmentDose-Response Relationship DrugProportional hazards modelbusiness.industrytumor necrosis factor-alfa inhibitorTumor Necrosis Factor-alphaPASIAdalimumabRetrospective cohort studypsoriasis arthritismedicine.diseaseConfidence intervalInfliximabSurgeryImmunoglobulin GMultivariate AnalysisANTI-TNFAbusiness2708Follow-Up Studies
researchProduct